methyl 2-[3-(4-bromo-2-formylphenoxy)phenyl]acetate | 1182350-36-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-[3-(4-bromo-2-formylphenoxy)phenyl]acetate
• 英文别名: [3-(4-bromo-2-formyl-phenoxy)-phenyl]-acetic acid methyl ester
• CAS: 1182350-36-2
• 化学式: C₁₆H₁₃BrO₄
• 分子量: 349.181
• InChiKey: SJQWPONHGMRLQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-[3-(4-bromo-2-formylphenoxy)phenyl]acetate 在 sodium tetrahydroborate 、 三溴化磷 、 sodium hydride 作用下， 以 1,4-二氧六环 、 甲醇 、 乙二醇二甲醚 、 mineral oil 为溶剂， 反应 30.33h， 生成 {3-[4-bromo-2-(2-oxooxazolidin-3-ylmethyl)-phenoxy]-phenyl}-acetic acid methyl ester
  参考文献：
  名称：

  [EN] CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN DCOMPOSÉS DIARYLIQUES CYCLIQUES EN TANT QU'ANTAGONISTES DE RÉCEPTEURS DE PROSTAGLANDINE D220091008US5668176ABAGLEY SCOTT W [US], et al19970916AAWO9503044A1MERCK & CO INC [US], et al19950202AAUS5334598ABAGLEY SCOTT W [US], et al19940802AA
  [FR] COMPOSÉS DIARYLIQUES CYCLIQUES EN TANT QU'ANTAGONISTES DE RÉCEPTEURS DE PROSTAGLANDINE D2

  摘要：

  公开号：

  WO2009102893A3
• 作为产物：
  描述：

  3-羟基苯乙酸 在 盐酸 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 19.0h， 生成 methyl 2-[3-(4-bromo-2-formylphenoxy)phenyl]acetate
  参考文献：
  名称：

  [EN] CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN DCOMPOSÉS DIARYLIQUES CYCLIQUES EN TANT QU'ANTAGONISTES DE RÉCEPTEURS DE PROSTAGLANDINE D220091008US5668176ABAGLEY SCOTT W [US], et al19970916AAWO9503044A1MERCK & CO INC [US], et al19950202AAUS5334598ABAGLEY SCOTT W [US], et al19940802AA
  [FR] COMPOSÉS DIARYLIQUES CYCLIQUES EN TANT QU'ANTAGONISTES DE RÉCEPTEURS DE PROSTAGLANDINE D2

  摘要：

  公开号：

  WO2009102893A3

文献信息

• [EN] FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS, COMPOSITIONS ET APPLICATIONS CORRESPONDANTES
  申请人：IMPETIS BIOSCIENCES LTD

  公开号：WO2018167800A1

  公开（公告）日：2018-09-20

  The present invention relates to fused bicyclic compounds that are inhibitors of GPR91, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91. The disclosure also relates to the process of preparation of the fused bicyclic compounds of Formula (I), and to pharmaceutical compositions containing them.

  本发明涉及融合的双环化合物，它们是GPR91的抑制剂，包括它们的立体异构体、互变异构体、前药、多型体、溶剂合物、药用可接受的盐以及含有它们的药物组合物。这些化合物在治疗、预防、预防接种、管理或辅助治疗与GPR91抑制相关的所有医学状况方面具有用处。本公开还涉及制备公式（I）的融合双环化合物的方法，以及含有它们的药物组合物。
• CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：Hutchinson John Howard

  公开号：US20110098302A1

  公开（公告）日：2011-04-28

  Described herein are compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD 2 receptors described herein, as well as methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了PGD2受体拮抗剂化合物。还描述了包括本文所述的PGD2受体拮抗剂在内的制药组合物和药物，以及使用这种PGD2受体拮抗剂，单独或与其他化合物结合，治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症的方法。
• AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：Hutchinson John Howard

  公开号：US20110130453A1

  公开（公告）日：2011-06-02

  Described herein are compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD 2 receptors. Also described herein are methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包括这些化合物的制药组合物和药物，用于治疗呼吸系统、心血管系统和其他依赖或介导于PGD2的疾病或病症。同时，还描述了使用这些PGD2受体拮抗剂，单独或与其他化合物联合使用的方法。
• Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
  申请人：Panmira Pharmaceuticals, LLC

  公开号：US08242145B2

  公开（公告）日：2012-08-14

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

  本文介绍了PGD2受体拮抗剂化合物。还介绍了包括这些PGD2受体拮抗剂在内的制药组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖或介导PGD2的疾病或病症。
• Aminoalkylphenyl antagonists of prostaglandin D2 receptors
  申请人：Hutchinson John Howard

  公开号：US08426449B2

  公开（公告）日：2013-04-23

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包括这些PGD2受体拮抗剂化合物的药物组合物和药物。此外，本文还描述了使用这些PGD2受体拮抗剂，单独或与其他化合物联合使用，治疗呼吸系统、心血管系统和其他依赖或介导于PGD2的疾病或病症的方法。